184 related articles for article (PubMed ID: 22820730)
1. Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Nagaraj H; Williams M; Wang H; Lee A; Sun E; Teo EL; Tan E; Goh KC; Dymock B
J Mol Model; 2013 Jan; 19(1):119-30. PubMed ID: 22820730
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).
Poulsen A; William A; Blanchard S; Lee A; Nagaraj H; Wang H; Teo E; Tan E; Goh KC; Dymock B
J Comput Aided Mol Des; 2012 Apr; 26(4):437-50. PubMed ID: 22527961
[TBL] [Abstract][Full Text] [Related]
3. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.
Goh KC; Novotny-Diermayr V; Hart S; Ong LC; Loh YK; Cheong A; Tan YC; Hu C; Jayaraman R; William AD; Sun ET; Dymock BW; Ong KH; Ethirajulu K; Burrows F; Wood JM
Leukemia; 2012 Feb; 26(2):236-43. PubMed ID: 21860433
[TBL] [Abstract][Full Text] [Related]
4. Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.
William AD; Lee AC; Goh KC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Lee CP; Wang H; Williams M; Sun ET; Hu C; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2012 Jan; 55(1):169-96. PubMed ID: 22148278
[TBL] [Abstract][Full Text] [Related]
5. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
[TBL] [Abstract][Full Text] [Related]
7. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
Ning CQ; Lu C; Hu L; Bi YJ; Yao L; He YJ; Liu LF; Liu XY; Yu NF
Eur J Med Chem; 2015 May; 95():104-15. PubMed ID: 25800646
[TBL] [Abstract][Full Text] [Related]
8. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.
Li Y; Ye T; Xu L; Dong Y; Luo Y; Wang C; Han Y; Chen K; Qin M; Liu Y; Zhao Y
Eur J Med Chem; 2019 Nov; 181():111590. PubMed ID: 31408808
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Yang T; Hu M; Qi W; Yang Z; Tang M; He J; Chen Y; Bai P; Yuan X; Zhang C; Liu K; Lu Y; Xiang M; Chen L
J Med Chem; 2019 Nov; 62(22):10305-10320. PubMed ID: 31670517
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritis.
William AD; Lee AC; Poulsen A; Goh KC; Madan B; Hart S; Tan E; Wang H; Nagaraj H; Chen D; Lee CP; Sun ET; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
J Med Chem; 2012 Mar; 55(6):2623-40. PubMed ID: 22339472
[TBL] [Abstract][Full Text] [Related]
12. Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
Niu P; Tao Y; Lin G; Xu H; Meng Q; Yang K; Huang W; Song M; Ding K; Ma D; Fan M
J Med Chem; 2024 Apr; 67(8):6099-6118. PubMed ID: 38586950
[TBL] [Abstract][Full Text] [Related]
13. Discovery of macrocyclic CDK2/4/6 inhibitors with improved potency and DMPK properties through a highly efficient macrocyclic drug design platform.
Meng F; Liu J; Cao Z; Yu J; Steurer B; Yang Y; Wang Y; Cai X; Zhang M; Ren F; Aliper A; Ding X; Zhavoronkov A
Bioorg Chem; 2024 May; 146():107285. PubMed ID: 38547721
[TBL] [Abstract][Full Text] [Related]
14. Potent antimyeloma activity of a novel ERK5/CDK inhibitor.
Álvarez-Fernández S; Ortiz-Ruiz MJ; Parrott T; Zaknoen S; Ocio EM; San Miguel J; Burrows FJ; Esparís-Ogando A; Pandiella A
Clin Cancer Res; 2013 May; 19(10):2677-87. PubMed ID: 23532886
[TBL] [Abstract][Full Text] [Related]
15. Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.
Chang Hsu Y; Ke YY; Shiao HY; Lee CC; Lin WH; Chen CH; Yen KJ; Hsu JT; Chang C; Hsieh HP
ChemMedChem; 2014 May; 9(5):953-61. PubMed ID: 24665000
[TBL] [Abstract][Full Text] [Related]
16. Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
Yuan X; Chen Y; Zhang W; He J; Lei L; Tang M; Liu J; Li M; Dou C; Yang T; Yang L; Yang S; Wei Y; Peng A; Niu T; Xiang M; Ye H; Chen L
J Med Chem; 2019 Apr; 62(8):4158-4173. PubMed ID: 30939008
[TBL] [Abstract][Full Text] [Related]
17. Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor.
Lou YJ
Acta Pharmacol Sin; 2012 Feb; 33(2):212-3. PubMed ID: 22231396
[No Abstract] [Full Text] [Related]
18. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.
Pallis M; Abdul-Aziz A; Burrows F; Seedhouse C; Grundy M; Russell N
Br J Haematol; 2012 Oct; 159(2):191-203. PubMed ID: 22934750
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Potent and Selective FLT3 Inhibitor (
Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
[TBL] [Abstract][Full Text] [Related]
20. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
Zhu J; Yang T; Tang M; Yang Z; Pei H; Ye H; Tang Y; Cheng Z; Lin P; Chen L
Biomed Pharmacother; 2021 May; 137():111373. PubMed ID: 33761599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
